The pooled HR with fixed-effect analysis was calculated as 1.74 (95% CI: 1.34-2.26, P=0.000), with moderate heterogeneity (I2 =25.6%, P=0.26), highlighting a reduced EFS rate in patients with AML and mutant ASXL1 (figure. Here, ASXL1 is linked to acute myeloid leukemia.